CONCISE REPORT

Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker

A A Deodhar¹, J Brabyn², I Pande², D L Scott³ and A D Woolf²

¹ Oregon Health Sciences University, Portland, OR, USA
² Royal Cornwall Hospital, Truro, UK
³ Kings College Hospital, London, UK

Correspondence to:
Correspondence to:
Dr A A Deodhar, Division of Arthritis and Rheumatic Diseases (OPO9), Oregon Health Sciences University, Portland, OR 97201, USA;
deodhara{at}ohsu.edu

Objective: To investigate whether hand bone mineral content (BMC) measurement is an outcome measure for RA and whether the early changes in hand BMC predict functional disability.

Methods: Tender and swollen joints in hands and body, HAQ score, Larsen score on hand radiographs, serum CRP, and hand BMC measurement by DXA were studied every six months for five years in 40 patients with early RA. At the final visit, patients completed the SF-36 and Duruoz hand function questionnaires.

Results: All patients completed two years and 29 completed five years’ follow up. Hand BMC worsened over the first three years (percentage loss from baseline: mean (SD) -5.5 (7.2), -7.5 (8.4), -9.8 (9.4)) and stabilised over last two years (–9.9 (8.8), -10 (7.8)). Baseline disease activity and function correlated with hand BMC loss at five years (swollen joints in hands: r=-0.38, p=0.043; swollen joints in body: r=-0.47, p=0.01; HAQ: r=-0.52, p=0.004). Percentage change in hand BMC over five years correlated with SF-36 physical function (r=0.61, p<0.01), hand function (r=-0.64, p<0.01), HAQ score (r=-0.63, p<0.01) at five years. Relative risk of bad hand functional outcome at five years was significantly higher for patients with hand BMC loss of 1.17 g (smallest detectable difference) than for patients with less bone loss within the first six months (OR=6.9, 95% CI 1.3 to 34.5, p<0.02).

Conclusion: Early loss of hand BMC in patients with RA is a composite marker of disease activity and functional status and can predict poor functional outcome.

Keywords: hand bone mineral content; bone densitometry; rheumatoid arthritis; outcome

Abbreviations: BMC, bone mineral content; DHI, Duruoz hand index; DMARDs, disease modifying antirheumatic drugs; DXA, dual energy x ray absorptiometry; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; SF-36, Short Form-36

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Goldring, S. R (2009). Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. Ann Rheum Dis 68: 297-299 [Full Text]  
• Hoff, M, Haugeberg, G, Odegard, S, Syversen, S, Landewe, R, van der Heijde, D, Kvien, T K (2009). Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis 68: 324-329 [Abstract] [Full Text]  
• Guler-Yuksel, M, Allaart, C F, Goekoop-Ruiterman, Y P M, de Vries-Bouwstra, J K, van Groenendael, J H L M, Mallee, C, de Bois, M H W, Breedveld, F C, Dijkmans, B A C, Lems, W F (2009). Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68: 330-336 [Abstract] [Full Text]  
• Haugeberg, G., Green, M. J, Conaghan, P. G, Quinn, M., Wakefield, R., Proudman, S. M, Stewart, S., Hensor, E., Emery, P. (2007). Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66: 1513-1517 [Abstract] [Full Text]  
• Haugeberg, G, Green, M J, Quinn, M A, Marzo-Ortega, H, Proudman, S, Karim, Z, Wakefield, R J, Conaghan, P G, Stewart, S, Emery, P (2006). Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65: 736-740 [Abstract] [Full Text]  
• Haugeberg, G., Strand, A., Kvien, T. K., Kirwan, J. R. (2005). Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis: Results From a Randomized Placebo-Controlled Trial. Arch Intern Med 165: 1293-1297 [Abstract] [Full Text]